Table 2.

Marine-derived anticancer drugs for which trials were discontinued or for which no active trials (NAT) were found in the ClinicalTrials.gov database.

Name	Synonym (s)	Natural Product or Derivative	Origin	Discontinued/Inactive	Reason for Discontinuation
ASG-15ME	AGS15E	Derivative	Cyanobacterium Caldora penicillata [15]	Discontinued	Unspecified [35]
Becatecarin	XL-119/NSC 655649/BMY 27557/BMS 181176	Rebeccamycin analogue	Marine actinomycete Saccharothrix aerocolonigenes [36]	Discontinued	Not superior to existing therapies [37]
CEP-2563	KT-8391	Staurosporine derivative		NAT
Didemnin B		Natural product	Tunicate Trididemnin cyanophorum [38]	Discontinued	Toxicity [39]
Edotecarin	J-107088/PF-804950/PHA-782615/ED-749	Derivative		NAT
Elisidepsin (Irvalec®)	PM02734	Structural analogue	Mollusk Elysia rufescens [40]	Discontinued	Strategic [41]
Enzastaurin	LY317615	Staurosporine derivative	Bacterium Streptomyces staurosporeus	Discontinued	Lack of efficacy [42]
Indusatumab vedotin	MLN-0264/TAK-0264	Derivative	Cyanobacterium Caldora penicillata [15]	Discontinued	Lack of efficacy [43]
Lestaurtinib	CEP-701	Staurosporine derivative	Bacterium Streptomyces staurosporeus	Discontinued	Strategic [41]
Lifastuzumab vedotin	DNIB0600A/Anti-NaPi2B ADC/RG7599	Derivative	Cyanobacterium Caldora penicillata [15]	Discontinued	Lack of efficacy [44]
Pipecolidepsin A		Natural product	Sponge Homophymia lamellose [13]	NAT
Stellatolide A		Natural product	Sponge Ecionemia acervus [45]	NAT
UCN-01	7-hydroxystaurosporine	Staurosporine analogue	Bacterium Streptomyces staurosporeus [29]	NAT
Vandortuzumab vedotin	DSTP-3086 S/RG-7450/thio-antiSTEAP1-MC-vc-PAB-MMAE	Derivative	Cyanobacterium Caldora penicillata [15]	NAT
Zalypsis	PM00104/PM-10450	Derivative	Sponge Netropsia sp. [15]	NAT